Drug intelligence / Profile preview

ClearQ (Anessa Pharma)

Development stage: Preclinical
Lead developer: Anessa Pharma
Modality: Small Molecules
Administration: Topical

Overview

ClearQ (CQ-QR3) is a photodynamic therapy (PDT) system developed by Anessa Pharma for the treatment of skin cancers, specifically Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC). The system consists of a topical drug combination (photosensitizer) that is applied to the skin and subsequently activated by a specific light irradiation device. This activation generates reactive oxygen species that selectively destroy malignant cells while minimizing damage to surrounding healthy tissue. The product is currently in clinical development, with the CQ-QR3 designation representing a milestone or later-stage iteration of the technology within Anessa Pharma's pipeline.

Brand names: ClearQ

Beyond the preview

Go deeper on ClearQ (Anessa Pharma).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ClearQ (Anessa Pharma).

Explore the full profile